These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 18057338

  • 1. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
    Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.
    N Engl J Med; 2007 Dec 06; 357(23):2359-70. PubMed ID: 18057338
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
    Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.
    AIDS; 2008 Sep 12; 22(14):1719-28. PubMed ID: 18690162
    [Abstract] [Full Text] [Related]

  • 3. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.
    J Clin Endocrinol Metab; 2010 Sep 12; 95(9):4291-304. PubMed ID: 20554713
    [Abstract] [Full Text] [Related]

  • 4. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
    Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.
    J Acquir Immune Defic Syndr; 2010 Mar 12; 53(3):311-22. PubMed ID: 20101189
    [Abstract] [Full Text] [Related]

  • 5. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A.
    AIDS; 2006 Apr 24; 20(7):1003-10. PubMed ID: 16603852
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
    Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S.
    JAMA; 2004 Jul 14; 292(2):210-8. PubMed ID: 15249570
    [Abstract] [Full Text] [Related]

  • 7. Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
    Berger D.
    Posit Aware; 2008 Jul 14; 19(3):31. PubMed ID: 18724445
    [No Abstract] [Full Text] [Related]

  • 8. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2003 Jun 14; 8(3):199-207. PubMed ID: 12924536
    [Abstract] [Full Text] [Related]

  • 9. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
    Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.
    JAMA; 2003 Jun 14; 312(4):380-9. PubMed ID: 25038357
    [Abstract] [Full Text] [Related]

  • 10. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
    Spooner LM, Olin JL.
    Ann Pharmacother; 2012 Feb 14; 46(2):240-7. PubMed ID: 22298602
    [Abstract] [Full Text] [Related]

  • 11. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
    Bickel M, Zangos S, Jacobi V, Lutz T, Knecht G, Goebel F, Staszewski S, Klauke S.
    HIV Med; 2006 Sep 14; 7(6):397-403. PubMed ID: 16903985
    [Abstract] [Full Text] [Related]

  • 12. Manipulation of the growth hormone axis in patients with HIV infection.
    Blackman MR.
    N Engl J Med; 2007 Dec 06; 357(23):2397-9. PubMed ID: 18057344
    [No Abstract] [Full Text] [Related]

  • 13. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
    Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.
    Clin Infect Dis; 2012 Jun 06; 54(11):1642-51. PubMed ID: 22495074
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug 06; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M, Tomlinson B.
    Curr Opin Investig Drugs; 2010 Oct 06; 11(10):1143-50. PubMed ID: 20872317
    [Abstract] [Full Text] [Related]

  • 16. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2007 Oct 06; 12(1):97-105. PubMed ID: 17503753
    [Abstract] [Full Text] [Related]

  • 17. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Ørskov H, Madsbad S, Nielsen JO, Iversen J.
    Eur J Clin Invest; 2004 Aug 06; 34(8):561-8. PubMed ID: 15305891
    [Abstract] [Full Text] [Related]

  • 18. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia.
    Thöni GJ, Fedou C, Brun JF, Fabre J, Renard E, Reynes J, Varray A, Mercier J.
    Diabetes Metab; 2002 Nov 06; 28(5):397-404. PubMed ID: 12461477
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 06; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 20. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
    Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P.
    J Clin Endocrinol Metab; 2005 Jul 06; 90(7):4075-80. PubMed ID: 15840750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.